Could a patient with target-like lower extremity lesions and respiratory symptoms have erythema multiforme?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Erythema Multiforme in the Context of Target-Like Lower Extremity Lesions and Respiratory Symptoms

Yes, erythema multiforme (EM) is a strong diagnostic consideration for this patient, particularly given the target-like lesions on the lower extremities, and the respiratory symptoms suggest a possible Mycoplasma pneumoniae trigger, which is a well-established cause of EM, especially in children. 1

Key Diagnostic Features Supporting EM

The characteristic presentation of EM includes:

  • Target or "iris" lesions consisting of a dark red center surrounded by a pink ring with well-defined circular appearance 1, 2
  • Three-zone target configuration with central dark papule/vesicle, pale zone, and erythematous halo 1
  • Predominant acral localization on extremities (especially extensor surfaces), spreading centripetally 3
  • Fixed lesions that remain for a minimum of 7 days, distinguishing EM from urticaria where individual lesions resolve within 24 hours 1, 3

Respiratory Symptoms and Mycoplasma Connection

The combination of target-like skin lesions with respiratory symptoms is particularly suggestive of Mycoplasma pneumoniae-associated EM:

  • Mycoplasma pneumoniae is a significant infectious trigger for EM, particularly common in children, and is associated with better prognosis 1
  • This organism can cause both respiratory illness and EM simultaneously 4, 3
  • Mycoplasma-induced EM may present with predominantly mucous membrane involvement with little or no cutaneous lesions (termed "Mycoplasma pneumoniae-associated mucositis") 1
  • The mechanism involves a hypersensitivity reaction with cytotoxic T lymphocytes inducing keratinocyte apoptosis, typically appearing 10 days after viral infection 1

Critical Differential Diagnoses to Exclude

Stevens-Johnson Syndrome (SJS)/Toxic Epidermal Necrolysis (TEN) must be differentiated from EM:

  • SJS/TEN features flat atypical targets or purpuric macules with epidermal detachment and positive Nikolsky sign 1
  • EM typically presents with raised atypical targets, predominantly on limbs and extremities 1
  • EM is mostly related to HSV or Mycoplasma infection, while SJS/TEN is usually triggered by drugs 1
  • EM has lower mortality and better prognosis compared to SJS/TEN 1

Other conditions in the differential include:

  • Rocky Mountain Spotted Fever (RMSF): Rash on palms and soles can occur with RMSF, but this typically begins as blanching pink macules evolving to maculopapules, not true target lesions 5
  • Coccidioidomycosis: Can present with erythema multiforme or erythema nodosum in endemic areas, but requires endemic exposure history 5
  • Tinea corporis: Presents with well-demarcated, sharply circumscribed patches with raised leading edge and satellite lesions, not true target morphology 2

Diagnostic Approach

Document lesion morphology precisely:

  • Photograph and mark borders to track progression 1
  • Look for the characteristic three-zone target configuration 1
  • Assess for symmetrical distribution on bilateral extremities 3

Histopathological confirmation when clinical diagnosis is uncertain:

  • EM shows variable epidermal damage ranging from individual cell apoptosis to confluent epidermal necrosis 1
  • Histopathology helps exclude other blistering dermatoses that may mimic EM 1

Investigate potential triggers:

  • Test for Mycoplasma pneumoniae given respiratory symptoms 1, 3
  • Consider HSV testing, as it is the most common cause of EM 1, 4
  • Review medication history for drugs that can precipitate EM (sulfonamides, penicillins, phenytoin, allopurinol) 4, 6

Management Considerations

For acute EM:

  • Symptomatic treatment with topical steroids or antihistamines 7, 3
  • Treat underlying infection if identified (Mycoplasma requires appropriate antibiotics) 3

For recurrent HSV-associated EM:

  • Prophylactic antiviral therapy is first-line treatment 7, 3
  • Note that topical acyclovir prophylaxis does not prevent further episodes; systemic therapy is required 4

For severe mucosal involvement:

  • May require hospitalization for intravenous fluids and electrolyte repletion 3
  • Antiseptic or anesthetic solutions for mucosal lesions 7

Common Pitfalls to Avoid

  • Do not confuse EM with urticaria; EM lesions remain fixed for at least 7 days versus urticarial lesions resolving within 24 hours 1, 3
  • Do not overlook Mycoplasma pneumoniae as a trigger when respiratory symptoms are present 1, 3
  • Do not misdiagnose as SJS/TEN based solely on the presence of target lesions; assess for epidermal detachment and Nikolsky sign 1
  • Do not dismiss the possibility of drug-induced EM; carefully review all medications 4, 6

References

Guideline

Erythema Multiforme Causes and Clinical Differentiation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Diagnosis and Treatment of Tinea Corporis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Erythema Multiforme: Recognition and Management.

American family physician, 2019

Research

Current Perspectives on Erythema Multiforme.

Clinical reviews in allergy & immunology, 2018

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Erythema multiforme.

American family physician, 1992

Research

Recent Updates in the Treatment of Erythema Multiforme.

Medicina (Kaunas, Lithuania), 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.